Addition of Nancy Chang to Board Will Benefit SciClone (SCLN), Maintain Buy - Aegis
Tweet Send to a Friend
Aegis Capital maintains a Buy on SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) with price target of $9 following the addition of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
